Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antibiotic combination
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J01DH55
|
| gptkbp:contains |
gptkb:meropenem
gptkb:vaborbactam |
| gptkbp:developedBy |
gptkb:The_Medicines_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
Carbavance
|
| gptkbp:indication |
carbapenem-resistant Enterobacteriaceae infections
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Vabomere
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
inhibits beta-lactamase enzymes |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:usedFor |
treatment of ventilator-associated bacterial pneumonia
treatment of complicated urinary tract infections treatment of hospital-acquired bacterial pneumonia |
| gptkbp:bfsParent |
gptkb:Rempex_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|